Cite
HARVARD Citation
De Marchi, F. et al. (n.d.). Concomitant monitoring of WT1 and FLT3‐ITD expression in FLT3‐ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker?. American journal of hematology. 92 (5), pp. E72-E74. [Online].